Rinat: Skirting the BBB problem

Using antibodies to address neurological conditions is rare, given the challenge of delivering large protein molecules across the blood brain barrier. Rinat Neuroscience Corp., which last week raised $40 million in a series B venture round, is avoiding the problem by